Vahanian & Associates Financial Planning’s Aquestive Therapeutics AQST Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.2M	Sell	591,608 -130,500	-18%	-$231K	4.72%	5
2023 Q3	$1.1M	Sell	722,108 -3,100	-0.4%	-$5.33K	3.55%	5
2023 Q2	$1.2M	Buy	725,208 +6,300	+0.9%	+$11.4K	3.78%	6
2023 Q1	$820K	Buy	718,908 +40,650	+6%	+$35.2K	2.27%	11
2022 Q4	$612K	Sell	678,258 -17,000	-2%	-$16K	2%	16
2022 Q3	$813K	Buy	695,258 +138,500	+25%	+$157K	2.8%	9
2022 Q2	$356K	Buy	556,758 +36,600	+7%	+$48.7K	1.53%	21
2022 Q1	$1.36M	Sell	520,158 -409,817	-44%	-$1.2M	3.14%	8
2021 Q4	$3.62M	Buy	+929,975	New	+$4.67M	2.92%	7

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return

Vahanian & Associates Financial Planning's AQST Position: Q4 2023 in Review

Vahanian & Associates Financial Planning reduced its Aquestive Therapeutics (AQST) stake by 18% in Q4 2023, selling an estimated $231K and leaving 591,608 shares worth $1.2M. The position accounts for 4.72% of the portfolio, ranked #5.

Vahanian & Associates Financial Planning first reported a position in AQST in Q4 2021 and has held it in 9 quarters since. The position peaked at $3.62M in Q4 2021. 57 funds tracked by Wall St. Rank hold AQST as of Q4 2023.

Vahanian & Associates Financial Planning held 591,608 shares of Aquestive Therapeutics worth $1.2M as of Q4 2023.
Vahanian & Associates Financial Planning sold 130,500 Aquestive Therapeutics shares in Q4 2023, an estimated $231K.
Aquestive Therapeutics made up 4.72% of Vahanian & Associates Financial Planning's portfolio in Q4 2023, its #5 holding.
Vahanian & Associates Financial Planning first reported a position in Aquestive Therapeutics in Q4 2021 and has held it in 9 quarters since.
Vahanian & Associates Financial Planning's Aquestive Therapeutics position peaked at $3.62M in Q4 2021.
57 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2023.

Based on Vahanian & Associates Financial Planning's 13F filing for Q4 2023, filed 25 Jan 2024.